IGF-1 LR3
A modified version of IGF-1 with extended half-life and reduced IGF binding protein affinity, used for muscle growth.
What is IGF-1 LR3?
IGF-1 LR3 is a modified form of insulin-like growth factor 1 with an arginine substitution at position 3 and a 13-amino acid N-terminal extension. These modifications dramatically reduce binding to IGF binding proteins (IGFBPs), increasing its bioavailability and half-life from ~15 minutes to ~20 hours. It is primarily used in research and by bodybuilders for muscle growth.
What IGF-1 LR3 Is Investigated For
IGF-1 LR3 is used almost exclusively for muscle growth and recovery in bodybuilding circles, with its 20–30 hour free-IGF-1 activity window producing far stronger and longer anabolic signaling than native IGF-1. The strongest evidence is mechanistic and preclinical — the IGFBP-bypass mechanism is well-validated, and animal studies consistently show enhanced anabolism, gut/organ growth, and sustained IGF-1R activation. There is no human clinical trial of LR3 for any indication, no dose-ranging data, and the 20–100 mcg bodybuilding protocols are derived from community practice rather than evidence. Unlike recombinant human IGF-1 (mecasermin/Increlex), which is approved for pediatric IGF-1 deficiency, LR3 is a chemically distinct analog that has never been submitted for regulatory approval anywhere. The real concerns — hypoglycemia from supraphysiologic IGF-1R activation, epidemiologic cancer risk from chronic IGF-1 elevation, preclinical organomegaly, and research-chemical supply integrity — are serious enough that LR3 sits at the high-risk end of commonly-used peptides.
History & Discovery
IGF-1 LR3 was engineered in the late 1980s and early 1990s by protein-chemistry groups seeking a more stable, IGFBP-resistant analogue of human IGF-1 for use as a cell-culture growth supplement and as a research tool in whole-animal anabolism studies. The molecule carries two deliberate modifications relative to native IGF-1: an arginine substitution for glutamate at position 3, which disrupts the IGFBP binding epitope, and a 13-amino-acid N-terminal extension borrowed from methionyl porcine growth hormone, which further reduces IGFBP affinity and extends circulating half-life. The combined result is a peptide with near-free IGF-1R agonism and a reported half-life of roughly 20–30 hours in humans versus minutes for native IGF-1. Much of the foundational work came out of groups including F. John Ballard and colleagues at CSIRO in Adelaide and aligns with the broader IGF-1 biology research program associated with Derek Le Roith at NIH. Recombinant human IGF-1 itself entered the clinic as mecasermin (Increlex) for severe primary IGF-1 deficiency in children and for short stature related to growth hormone insensitivity. LR3, by contrast, never pursued a therapeutic indication — it remained a laboratory reagent until the 2000s, when it migrated into bodybuilding and research-chemical supply channels as a muscle-growth compound outside any regulatory framework.
How It Works
IGF-1 LR3 is a supercharged version of the body's main growth signal. It promotes muscle cell growth and even the creation of new muscle cells, while lasting much longer in the body than natural IGF-1.
IGF-1 LR3 activates the IGF-1 receptor (IGF-1R) with similar affinity to native IGF-1 but with dramatically reduced IGFBP sequestration. IGF-1R activation triggers PI3K/Akt/mTOR signaling for protein synthesis and cell growth, and Ras/MAPK/ERK for cell proliferation. The extended bioavailability means prolonged mTOR activation and satellite cell stimulation, potentially promoting muscle hyperplasia (new fiber formation) in addition to hypertrophy.
Evidence Snapshot
Human Clinical Evidence
Very limited. No human clinical trials specific to LR3-IGF-1. Primarily used in research settings.
Animal / Preclinical
Extensive. Dozens of preclinical studies demonstrate enhanced potency over native IGF-1, anabolic effects on muscle and gut tissue, enhanced wound healing, and favorable pharmacokinetics across multiple species.
Mechanistic Rationale
Strong. IGF-1R signaling is one of the best-characterized growth factor pathways. The reduced IGFBP binding mechanism is well-validated.
Research Gaps & Open Questions
What the current literature has not yet settled about IGF-1 LR3:
- 01No human Phase II or III trials of LR3 for any indication — all human exposure is off-label or via research-chemical channels with no systematic safety surveillance.
- 02Long-term cancer risk — epidemiology links elevated IGF-1 to several malignancies, but the specific dose-response and cumulative-exposure relationship for episodic supraphysiologic LR3 use is unquantified.
- 03Dose-response for lean tissue gain versus adverse effects — the bodybuilding 20–100 mcg range is not anchored in any human dose-ranging study; minimum effective and maximum tolerated doses are unknown.
- 04Organomegaly thresholds — preclinical work shows gut, heart, and kidney growth with chronic IGF-1 analogue exposure, but human thresholds for clinically meaningful organ changes are uncharacterized.
- 05Injection-site fibrotic changes — repeated SC or IM LR3 injection is anecdotally associated with local tissue changes; systematic imaging or histologic study in humans is absent.
- 06Reliability of research-chemical supply — purity, correct peptide identity, and endotoxin content of commercially sold LR3 are not subject to pharmaceutical-grade QA, and contamination or misidentification has been documented in peptide market studies.
Forms & Administration
SC or IM injection. Research doses typically 20-100mcg/day. Often used in cycles of 4-6 weeks. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Bodybuilding-community protocols most commonly describe 20–50 mcg per injection, with some users going up to 80–100 mcg. These numbers come from online community sources, not dose-ranging trials — there is no validated human therapeutic dose for LR3. Doses above ~50 mcg substantially raise the risk of symptomatic hypoglycemia because LR3's 20–30 hour free IGF-1 activity window is pharmacologically unlike anything native physiology produces.
Frequency
Most described protocols run once daily, often timed post-workout or with a carbohydrate-containing meal to blunt hypoglycemic risk. Some users split into twice-daily dosing. The long half-life means steady-state IGF-1R activation builds across days — intra-day timing likely matters less than total daily exposure.
Timing Considerations
Time of day
Ties to training schedule rather than clock time. Post-workout is the most common injection window on training days; non-training days use any consistent time.
Relative to meals
Typically injected with a carbohydrate-and-protein meal (commonly post-workout) — both to ride endogenous insulin for amplified anabolic signaling and to buffer LR3's pronounced hypoglycemic risk. Fasted injection substantially raises the chance of symptomatic hypoglycemia.
Relative to exercise
Post-workout is the standard pattern. LR3's extended systemic half-life makes exact injection-site locality less important than with short-acting IGF-1-DES, though some users still inject near a trained muscle group.
Cycle Length
Community protocols typically cap continuous use at 4 weeks, followed by at least 4 weeks off. Rationale offered is that chronic supraphysiologic IGF-1R signaling is implicated in organ overgrowth (gut, heart, kidney) in preclinical models, and that receptor downregulation may blunt effect over longer runs. These are plausible concerns, but the 4-week convention is not derived from human evidence.
Protocol Notes
LR3 is supplied as a lyophilized powder requiring reconstitution in bacteriostatic water, with subcutaneous injection via insulin syringe the most commonly described route. Intramuscular injection near a trained muscle is sometimes described to attempt localization, but LR3's systemic half-life makes true site-specificity much weaker than with IGF-1 DES. Hypoglycemia monitoring is the single most important practical issue. IGF-1R activation produces insulin-like glucose lowering with a time course much longer than insulin itself; users reporting symptoms (shakiness, confusion, sweating) hours after a dose is common. Blood-glucose monitoring and access to rapid-acting carbohydrate are reasonable precautions any honest clinician would insist on. Protocols published in the bodybuilding space are not medical advice. The combination of research-chemical sourcing (variable purity, no USP assay), a peptide with pronounced hypoglycemic potential, and a theoretical long-term mitogenic risk profile makes this one of the higher-risk peptides in widespread non-medical use.
These numbers describe what is circulating in the community, not a prescription. IGF-1 LR3 is not FDA-approved for any indication. Any actual use should be under the direct supervision of a qualified healthcare provider who can monitor glucose, assess cancer risk, and evaluate whether the risk-benefit profile is remotely justifiable.
Timeline of Effects
Onset
Acute hypoglycemic effects can appear within hours of the first dose. Anabolic effects — increased fullness, pump, and nitrogen retention — are commonly reported within the first week of daily use, though objective measurement in humans is absent. Animal data supports rapid onset of IGF-1R-mediated protein-synthesis signaling.
Peak Effect
Muscle-growth-related effects are most often described in the 3–4 week window of a typical 4-week cycle. Published animal work uses similar timeframes and shows accrual of lean tissue that plateaus with continued exposure, consistent with the receptor-downregulation concern.
After Discontinuation
Circulating LR3 clears over several days given its 20–30 hour half-life. Muscle and connective-tissue adaptations persist as long as training and nutrition support them, but the sustained IGF-1R tone disappears. Some users report a post-cycle dip in recovery and body composition, which mechanistically is consistent with withdrawal of a supraphysiologic anabolic signal.
Common Questions
Who IGF-1 LR3 Is NOT For
- •Active or recent-history cancer, and any personal or strong family history of hormone-sensitive cancers — IGF-1R activation is mitogenic, and chronic supraphysiologic IGF-1 signaling is epidemiologically associated with several malignancies.
- •Diabetes or impaired glucose regulation — LR3's insulin-like glucose-lowering action compounds hypoglycemic risk and makes glycemic control unpredictable.
- •Pregnancy and breastfeeding — no human pregnancy or lactation safety data; IGF-1 is a central regulator of fetal growth, making perturbation with a long-acting analogue categorically unwise.
- •Pediatric use (under 18) outside approved mecasermin therapy — growth-plate, organ, and cancer-risk considerations in developing patients are serious.
- •Active acromegaly, untreated pituitary tumor, or any condition of IGF-1 excess — adding exogenous IGF-1R agonism to an already dysregulated axis is contraindicated.
- •Retinopathy — IGF-1 signaling is implicated in proliferative retinal vascular disease; patients with diabetic or other proliferative retinopathy should avoid IGF-1 analogues.
Drug & Supplement Interactions
Clinical interaction data for LR3 specifically is essentially absent; what follows is extrapolated from the known pharmacology of recombinant IGF-1 (mecasermin) and from general IGF-1R biology. The most clinically relevant interaction is with insulin and insulin secretagogues (sulfonylureas, meglitinides, GLP-1 receptor agonists, SGLT2 inhibitors in some patients): LR3 meaningfully lowers blood glucose on its own, and combining it with glucose-lowering drugs can precipitate severe hypoglycemia. Patients on any diabetes medication should not use LR3 without endocrinologist oversight. LR3 may potentiate or counteract growth hormone and GH secretagogues (sermorelin, tesamorelin, ipamorelin, CJC-1295, MK-677) depending on timing and endpoint — GH-induced IGF-1 plus exogenous LR3 can push total IGF-1R activation well into pathologic range, with corresponding risks for organomegaly and glucose dysregulation. Concurrent use with anabolic-androgenic steroids is common in the bodybuilding space; AAS do not directly interact with IGF-1R but compound cardiovascular load, cancer-risk considerations, and organomegaly concerns. Corticosteroids may blunt anabolic response. Any patient taking anti-neoplastic therapy — particularly IGF-1R-targeting agents in oncology trials — should not use LR3.
Safety Profile
Common Side Effects
Cautions
- • Significant hypoglycemia risk
- • May promote growth of existing tumors
- • Not FDA-approved
- • Organ growth with chronic use
What We Don't Know
Long-term safety is poorly characterized. Theoretical cancer risk from chronic IGF-1R activation.
Legal Status
United States
IGF-1 LR3 is not FDA-approved for any medical indication. Recombinant human IGF-1 (mecasermin, Increlex) is approved for severe primary IGF-1 deficiency in children, but LR3 is a separate, non-approved analogue. LR3 is sold in the US almost exclusively through research-chemical suppliers, who label it 'not for human use.' Distribution for human consumption is not authorized. It is not a controlled substance, but selling it for human use is an unapproved drug violation under the FD&C Act.
International
Not approved as a medicine in the EU, UK, Canada, or Australia. Australia's TGA treats it as a Schedule 4 prescription-only substance and has pursued enforcement against unauthorized sellers. Importation for personal use is restricted or prohibited in most developed regulatory jurisdictions.
Sports & Competition
Prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances, and mimetics), which explicitly covers IGF-1 and its analogues. Athletes subject to WADA, USADA, UKAD, or equivalent testing frameworks should consider LR3 categorically prohibited in and out of competition. Detection windows for IGF-1 analogues continue to extend as mass-spectrometry methods improve.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
IGF-1 LR3 is just a stronger, safer version of the body's natural IGF-1.
Reality
It is stronger in the sense that IGFBP sequestration is bypassed and half-life is dramatically extended — but those same features are precisely what make it pharmacologically unlike native IGF-1. Physiologic IGF-1 is tightly regulated by IGFBPs in minute-scale feedback loops; LR3 imposes tonic, unregulated IGF-1R activation for a day or more per dose. Safer is not the right word.
Myth
Short cycles eliminate the cancer risk.
Reality
Epidemiologic evidence linking elevated IGF-1 to several cancers comes from chronic population-level exposure. No one has characterized the cancer-risk impact of repeated short LR3 cycles in humans, and extrapolating from 'low-risk' based on cycle length is speculation, not evidence. A personal or family history of hormone-sensitive cancer is a serious reason to avoid the compound entirely.
Myth
Bodybuilding doses of LR3 don't produce meaningful hypoglycemia.
Reality
Hypoglycemia is one of the most reliably reported effects, including at 20–40 mcg doses, and it can be delayed by hours because of the long half-life. Symptoms have sent users to emergency departments. Dismissing the glucose-lowering effect as minor is dangerous.
Myth
Because IGF-1 is an approved drug (Increlex), LR3 is basically approved too.
Reality
Mecasermin (Increlex) is recombinant human IGF-1, approved for a narrow pediatric indication under strict monitoring. IGF-1 LR3 is a chemically distinct analogue with different pharmacokinetics, and it has never been submitted for any regulatory approval. Conflating the two is a marketing claim, not a regulatory fact.
Published Research
20 studiesRevolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration
IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep
Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.
Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets
Impaired muscle regeneration and myoblast differentiation in mice with a muscle-specific KO of IGF-IR
Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy
The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology
Preferential intestinal delivery of long[Arg3] insulin-like growth factor (LR3IGF-I) over IGF-I in preweaning and adult rats.
Insulin-like growth factor-I and analogues increase growth in artificially-reared neonatal pigs.
Transport of circulating IGF-I and LR3IGF-I from blood to extracellular wound fluid sites in rats.
The role of insulin-like growth factors in small intestinal cell growth and development.
Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs.
IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys.
Effects of insulin-like growth factor-I and LR3IGF-I on regional blood flow in normal rats.
Effects of chronic renal failure on plasma clearance of insulin-like growth factor I, des-(1-3)IGF-I, and LR3IGF-I.
Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection.
Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats.
Prolonged administration of IGF peptides enhances growth of gastrointestinal tissues in normal rats.
Treatment with IGF-I peptides improves function of the remnant gut following small bowel resection in rats.
Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects.
Quick Facts
- Class
- Growth Factor Analogue
- Tier
- C
- Evidence
- Emerging
- Safety
- Limited Data
- Updated
- Mar 2026
- Citations
- 20PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.